Surveillance and treatment of non-muscle-invasive bladder cancer in the USA

Advances in Urology

Volumn , Issue , 2012, Pages

  Barocas, Daniel A ^a   Globe, Denise R ^b   Colayco, Danielle C ^b   Onyenwenyi, Ahunna ^b   Bruno, Amanda S ^c   Bramley, Thomas J ^c   Spear, Rachel J ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b ALLERGAN INC   (United States)

^c XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862294941     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/421709     Document Type: Review

References (86)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Avritscher E. B. C., Cooksley C. D., Grossman H. B., Sabichi A. L., Hamblin L., Dinney C. P., Elting L. S., Clinical model of lifetime cost of treating bladder cancer and associated complications Urology 2006 68 3 549 553 (Pubitemid 44436509)
3. Witjes J. A., Hendricksen K., Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results European Urology 2008 53 1 45 52 (Pubitemid 350167566)
4. Pashos C. L., Botteman M. F., Laskin B. L., Redaelli A., Bladder cancer: epidemiology, diagnosis, and management Cancer Practice 2002 10 6 311 322 (Pubitemid 35231626)
5. Koya M. P., Simon M. A., Soloway M. S., Complications of intravesical therapy for urothelial cancer of the bladder Journal of Urology 2006 175 6 2004 2010 (Pubitemid 43668507)
6. Kilbridge K. L., Kantoff P., Intravesical therapy for superficial bladder cancer: is it a wash? Journal of Clinical Oncology 1994 12 1 1 4 (Pubitemid 24020611)
7. Kamat A. M., Lamm D. L., Intravesical therapy for bladder cancer Urology 2000 55 2 161 168 (Pubitemid 30069908)
8. Lamm D. L., Blumenstein B. A., Crissman J. D., Montie J. E., Gottesman J. E., Lowe B. A., Sarosdy M. F., Bohl R. D., Grossman H. B., Beck T. M., Leimert J. T., Crawford E. D., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study Journal of Urology 2000 163 4 1124 1129 (Pubitemid 30169376)
9. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., Rischmann P., The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized prospective, double-blind, placebo controlled, multicenter study Journal of Urology 2006 176 3 935 939 (Pubitemid 44142611)
10. Schmidbauer J., Lindenau G., Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often? Current Opinion in Urology 2008 18 5 504 507
11. Lamm D., Bladder cancer: improving care with better classification and risk stratification Journal of Urology 2007 178 4 1146 1147 (Pubitemid 47368475)
12. van Rhijn B. W. G., Burger M., Lotan Y., Solsona E., Stief C. G., Sylvester R. J., Witjes J. A., Zlotta A. R., Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy European Urology 2009 56 3 430 442
13. Comprehensive Cancer Network National, Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2, 2011
14. Babjuk M., Oosterlinck W., Sylvester R., Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology, 2011
15. Madeb R., Golijanin D., Noyes K., Fisher S., Stephenson J. J., Long S. R., Knopf J., Lyman G. H., Messing E. M., Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors Cancer 2009 115 12 2660 2670
16. Hall M. C., Chang S. S., Dalbagni G., Pruthi R. S., Seigne J. D., Skinner E. C., Wolf J. S., Schellhammer P. F., Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update Journal of Urology 2007 178 6 2314 2330 (Pubitemid 350080987)
17. Huang G. J., Hamilton A. S., Lo M., Stein J. P., Penson D. F., Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project Journal of Urology 2008 180 2 520 524
18. Chamie K., Saigal C. S., Lai J., Hanley J. M., Setodji C. M., Konety B. R., Litwin M. S., Compliance with guidelines for patients with bladder cancer: variation in the delivery of care Cancer 2011 117 23 5392 5401
19. Grossman H. B., ODonnell M. A., Cookson M. S., Greenberg R. E., Keane T. E., Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer Reviews in Urology 2008 10 4 281 289
20. Metwalli A. R., Kamat A. M., Controversial issues and optimal management of stage T1G3 bladder cancer Expert Review of Anticancer Therapy 2006 6 8 1283 1294 (Pubitemid 44304696)
21. Herr H., Konety B., Stein J., Sternberg C. N., Wood D. P., Optimizing outcomes at every stage of bladder cancer: do we practice it? Urologic Oncology: Seminars and Original Investigations 2009 27 1 72 74
22. Gallagher B. L., Joudi F. N., Maym J. L., O'Donnell M. A., Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy Urology 2008 71 2 297 301 (Pubitemid 351282357)
23. Huncharek M., Kupelnick B., Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation American Journal of Clinical Oncology 2003 26 4 402 407 (Pubitemid 36962087)
24. Weiss C., Ott O. J., Wittlinger M., Krause S. F., Fietkau R., Sauer R., Rdel C., Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy Strahlentherapie und Onkologie 2008 184 9 443 449
25. Botteman M. F., Pashos C. L., Redaelli A., Laskin B., Hauser R., The health economics of bladder cancer: a comprehensive review of the published literature PharmacoEconomics 2003 21 18 1315 1330 (Pubitemid 38041357)
26. Sievert K. D., Amend B., Nagele U., Schilling D., Bedke J., Horstmann M., Hennenlotter J., Kruck S., Stenzl A., Economic aspects of bladder cancer: what are the benefits and costs? World Journal of Urology 2009 27 3 295 300
27. Lee C., Globe D., Colayco D., Gilmore A., Bramley T., Economic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer Proceedings of the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research May 2011 Baltimore, Md, USA
28. Levels of Evidence Working Group OCEBM, The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine, http://www.cebm.net/index. aspx?o=5653
29. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Kiemeney L., Kriegmair M., Montironi R., Murphy W. M., Sesterhenn I. A., Tachibana M., Weider J., Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 2005 66 6 4 34 (Pubitemid 43049607)
30. Gallagher D. J., Milowsky M. I., Bladder cancer Current Treatment Options in Oncology 2009 10 3-4 205 215
31. Dovedi S. J., Davies B. R., Emerging targeted therapies for bladder cancer: a disease waiting for a drug Cancer and Metastasis Reviews 2009 28 3-4 355 367
32. Clark P. E., Bladder cancer Current Opinion in Oncology 2007 19 3 241 247 (Pubitemid 46597484)
33. Zlotta A. R., Fleshner N. E., Jewett M. A., The management of BCG failure in non-muscle-invasive bladder cancer: an update Journal of the Canadian Urological Association 2009 3 6 S199 S205
34. Barocas D. A., Clark P. E., Bladder cancer Current Opinion in Oncology 2008 20 3 307 314 (Pubitemid 351507552)
35. Donat S. M., Evaluation and follow-up strategies for superficial bladder cancer Urologic Clinics of North America 2003 30 4 765 776 (Pubitemid 37485191)
36. Amiel G. E., Lerner S. P., Combining surgery and chemotherapy for invasive bladder cancer: current and future directions Expert Review of Anticancer Therapy 2006 6 2 281 291 (Pubitemid 44192939)
37. Gwynn E. S., Clark P. E., Bladder cancer Current Opinion in Oncology 2006 18 3 277 283 (Pubitemid 43740424)
38. Martin F. M., Kamat A. M., Definition and management of patients with bladder cancer who fail BCG therapy Expert Review of Anticancer Therapy 2009 9 6 815 820
39. Bochner B. H., Optimal timing of radical cystectomy for patients with T1 bladder cancer Urologic Oncology: Seminars and Original Investigations 2009 27 3 329 331
40. Patard J. J., Rodriguez A., Lobel B., The current status of intravesical therapy for superficial bladder cancer Current Opinion in Urology 2003 13 5 357 362 (Pubitemid 37094282)
41. Smaldone M. C., Gayed B. A., Tomaszewski J. J., Gingrich J. R., Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer Minerva Urologica e Nefrologica 2009 61 2 71 89
42. Smaldone M. C., Casella D. P., Welchons D. R., Gingrich J. R., Investigational therapies for non-muscle invasive bladder cancer Expert Opinion on Investigational Drugs 2010 19 3 371 383
43. Nieder A. M., Brausi M., Lamm D., O'Donnell M., Tomita K., Woo H., Jewett M. A. S., Management of stage T1 tumors of the bladder: International Consensus Panel Urology 2005 66 6 108 125 (Pubitemid 43049612)
44. Bhle A., Jocham D., Bock P. R., Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity Journal of Urology 2003 169 1 90 95 (Pubitemid 35461559)
45. Sylvester R. J., Oosterlinck W., Van Der Meijden A. P. M., A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials Journal of Urology 2004 171 6 2186 2190 (Pubitemid 38625431)
46. Hendricksen K., Witjes J. A., Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer Current Opinion in Urology 2007 17 5 352 357 (Pubitemid 47351133)
47. Howlader N., Noone A. M., Krapcho M., SEER Cancer Statistics Review, 19752008. National Cancer Institute, Bethesda, Md, USA, 2011, http://seer.cancer.gov/csr/19752008/
48. Brookfield K. F., Cheung M. C., Gomez C., Yang R., Nieder A. M., Lee D. J., Koniaris L. G., Survival disparities among African American women with invasive bladder cancer in Florida Cancer 2009 115 18 4196 4209
49. Borden L. S., Clark P. E., Hall M. C., Bladder cancer Current Opinion in Oncology 2005 17 3 275 280 (Pubitemid 40586170)
50. Ploeg M., Aben K. K. H., Kiemeney L. A., The present and future burden of urinary bladder cancer in the world World Journal of Urology 2009 27 3 289 293
51. Sylvester R. J., Van Der Meijden A. P. M., Oosterlinck W., Witjes J. A., Bouffioux C., Denis L., Newling D. W. W., Kurth K., Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials European Urology 2006 49 3 466 475 (Pubitemid 43259554)
52. Haukaas S., Dhlin L., Maartmann-Moe H., Ulvik N. M., The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience BJU International 1999 83 9 957 963 (Pubitemid 29271860)
53. Wade M., Seigne J. D., Surgical management of bladder cancer in 2003 Expert Review of Anticancer Therapy 2003 3 6 781 792 (Pubitemid 37540535)
54. Herr H. W., Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome Journal of Urology 2000 163 1 60 62
55. Cookson M. S., Herr H. W., Zhang Z. F., Soloway S., Sogani P. C., Fair W. R., The treated natural history of high risk superficial bladder cancer: 15-year outcome Journal of Urology 1997 158 1 62 67 (Pubitemid 27251595)
56. Holmang S., Hedelin H., Anderstrom C., Johansson S. L., Soloway M. S., The relationship among multiple recurrences, progression and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years Journal of Urology 1995 153 6 1823 1827
57. Lamm D., Colombel M., Persad R., Soloway M., Bhle A., Palou J., Witjes J. A., Akaza H., Buckley R., Brausi M., Clinical practice recommendations for the management of non-muscle invasive bladder cancer European Urology, Supplements 2008 7 10 651 666
58. Solsona E., Iborra I., Rics J. V., Monrs J. L., Casanova J., Dumont R., Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup Journal of Urology 1999 161 4 1120 1123 (Pubitemid 29426099)
59. Tolley D. A., Parmar M. K. B., Grigor K. M., Lallemand G., Beynon L. L., Fellows S. J., Freedman L. S., Hall R. R., Hargreave T. B., Munson K., Newling D. W. W., Richards B., Robinson M. R. G., Rose M. B., Smith P. H., Williams J. L., Whelan P., The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup Journal of Urology 1996 155 4 1233 1238 (Pubitemid 26081202)
60. Sylvester R. J., Oosterlinck W., Witjes J. A., The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials European Urology 2008 53 4 709 719
61. Kim H. H., lee C., Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor Journal of Urology 1989 141 6 1337 1340 (Pubitemid 19151790)
62. Kalsi J., Harland S. J., Feneley M. R., Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma Expert Opinion on Drug Delivery 2008 5 1 137 145 (Pubitemid 351234114)
63. Di Stasi S. M., Giannantoni A., Stephen R. L., Capelli G., Navarra P., Massoud R., Vespasiani G., Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study Journal of Urology 2003 170 3 777 782 (Pubitemid 36999554)
64. Malmstrm P. U., Sylvester R. J., Crawford D. E., Friedrich M., Krege S., Rintala E., Solsona E., Di Stasi S. M., Witjes J. A., An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer European Urology 2009 56 2 247 256
65. Sylvester R. J., Van Der Meijden A. P. M., Lamm D. L., Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials Journal of Urology 2002 168 5 1964 1970
66. Chang S. S., Cookson M. S., Radical cystectomy for bladder cancer: the case for early intervention Urologic Clinics of North America 2005 32 2 147 155 (Pubitemid 40603289)
67. Van Der Meijden A. P. M., Sylvester R. J., Oosterlinck W., Hoeltl W., Bono A. V., Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial European Urology 2003 44 4 429 434 (Pubitemid 37185667)
68. Stein J. P., Lieskovsky G., Cote R., Groshen S., Feng A. C., Boyd S., Skinner E., Bochner B., Thangathurai D., Mikhail M., Raghavan D., Skinner D. G., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients Journal of Clinical Oncology 2001 19 3 666 675 (Pubitemid 32120143)
69. Joudi F. N., O'Donnell M. A., Second-line intravesical therapy versus cystectomy for bacille Calmette-Gué (BCG) failures Current Opinion in Urology 2004 14 5 271 275 (Pubitemid 39141983)
70. Shabsigh A., Korets R., Vora K. C., Brooks C. M., Cronin A. M., Savage C., Raj G., Bochner B. H., Dalbagni G., Herr H. W., Donat S. M., Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology European Urology 2009 55 1 164 176
71. van der Heijden A. G., Moonen P. M. J., Cornel E. B., Vergunst H., de Reijke T. M., van Boven E., Barten E. J., Puri R., van Kalken C. K., Witjes J. A., Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response Journal of Urology 2006 176 4 1349 1353 (Pubitemid 44307194)
72. Maffezzini M., Campodonico F., Canepa G., Capponi G., Fontana V., Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate risk, transitional cell carcinoma of the bladder European Urology 2007 51 4 956 961 (Pubitemid 46281414)
73. Laudano M. A., Barlow L. J., Murphy A. M., Petrylak D. P., Desai M., Benson M. C., McKiernan J. M., Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy Urology 2010 75 1 134 137
74. Lee C., Gruschkus S., Colayco D., Bramley T., Globe D., Treatment patterns and costs of treating non-muscle invasive bladder cancer (NMIBC) Proceedings of the 12th Annual Meeting of the Society of Urologic Oncology November-December 2011 Rockville, Md, USA
75. Chamie K., Saigal C. S., Lai J., Hanley J., Setodji C. M., Konety B. R., Litwin M. S., Quality of care in patients with bladder cancer: the need to improve care beyond a case report Proceedings of the American Urological Association Annual Meeting May 2011 Washington, DC, USA
76. Mariotto A. B., Robin Yabroff K., Shao Y., Feuer E. J., Brown M. L., Projections of the cost of cancer care in the united states: 20102020 Journal of the National Cancer Institute 2011 103 2 117 128
77. Lotan Y., Kamat A. M., Porter M. P., Robinson V. L., Shore N., Jewett M., Schelhammer P. F., White R. D., Quale D., Lee C. T., Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology Cancer 2009 115 18 4096 4103
78. Reeve B. B., Potosky A. L., Smith A. W., Han P. K., Hays R. D., Davis W. W., Arora N. K., Haffer S. C., Clauser S. B., Impact of cancer on health-related quality of life of older americans Journal of the National Cancer Institute 2009 101 12 860 868
79. Williams-Cox D., A mixed-method study into quality of life for bladder cancer patients Professional Nurse 2004 19 6 343 347
80. Botteman M. F., Pashos C. L., Hauser R. S., Laskin B. L., Redaelli A., Quality of life aspects of bladder cancer: a review of the literature Quality of Life Research 2003 12 6 675 688 (Pubitemid 37094030)
81. Parkinson J. P., Konety B. R., Health related quality of life assessments for patients with bladder cancer Journal of Urology 2004 172 6 2130 2136 (Pubitemid 39507478)
82. Yoshimura K., Utsunomiya N., Ichioka K., Matsui Y., Terai A., Arai Y., Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey Urology 2005 65 2 290 294 (Pubitemid 40248015)
83. Bhle A., Balck F., Von Wietersheim J., Jocham D., The quality of life during intravesical bacillus Calmette-Guerin therapy Journal of Urology 1996 155 4 1221 1226 (Pubitemid 26081200)
84. Mack D., Frick J., Quality of life in patients undergoing bacille Calmette-Guérin therapy for superficial bladder cancer British Journal of Urology 1996 78 3 369 371
85. Kulkarni G. S., Alibhai S. M. H., Finelli A., Fleshner N. E., Jewett M. A. S., Lopushinsky S. R., Bayoumi A. M., Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer Cancer 2009 115 23 5450 5459
86. Barocas D., Globe D., Colayco D., Gilmore A., Bramley T., Humanistic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer Proceedings of the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research May 2011 Baltimore, Md, USA